SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-013491
Filing Date
2023-08-07
Accepted
2023-08-07 07:30:46
Documents
71
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20230630x10q.htm   iXBRL 10-Q 1808963
2 EX-3.2 acrs-20230630xex3d2.htm EX-3.2 11632
3 EX-31.1 acrs-20230630xex31d1.htm EX-31.1 15617
4 EX-31.2 acrs-20230630xex31d2.htm EX-31.2 15657
5 EX-32.1 acrs-20230630xex32d1.htm EX-32.1 9512
  Complete submission text file 0001558370-23-013491.txt   7835988

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20230630.xsd EX-101.SCH 40510
7 EX-101.CAL acrs-20230630_cal.xml EX-101.CAL 46175
8 EX-101.DEF acrs-20230630_def.xml EX-101.DEF 193309
9 EX-101.LAB acrs-20230630_lab.xml EX-101.LAB 438613
10 EX-101.PRE acrs-20230630_pre.xml EX-101.PRE 307052
65 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230630x10q_htm.xml XML 1576502
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 231145595
SIC: 2834 Pharmaceutical Preparations